Gastrointestinal Disease

Ingestible ‘smart pill’ may pinpoint GI disorders

An ingestible smart pill uses magnetic fields to track its movement through the GI tract, potentially facilitating the treatment of GI motility disorders.

February 13, 2023

Thermo Fisher Scientific launches CE-IVD marked panel to detect most common gastrointestinal bacteria

With results available in about two hours at greater than 98% sensitivity and specificity, the panel compares favorably with the culturing of samples in a lab, which can take up to two weeks, the firm said.

October 10, 2022

Pharos Capital sells TechLab to SSI Diagnostica

TechLab produces tests for infectious diseases, intestinal inflammation, and parasites, as well as gastrointestinal conditions such as inflammatory bowel disease, irritable bowel syndrome, and Escherichia coli infection. It also offers a test for Clostridioides difficile called Quik Chek, according to Pharos Capital.

August 21, 2022

DiaSorin first-half revenues surge on non-COVID testing

Revenues were driven in part by sales of products from Luminex, acquired last July for $1.8 billion.

August 3, 2022

Guardant touts studies on liquid biopsy tests at ASCO meeting

Data from a large, prospective, observational study shows that Guardant Reveal can detect molecular residual disease (MRD) prior to disease recurrence with an average lead time greater than six months when performed after curative intent surgery for stage II-III colorectal cancer, Guardant said.

January 19, 2022

How will the Quidel, Ortho deal impact the point-of-care market?

The company that can impact the point-of-care market drives the future. The COVID-19 pandemic made that point visible, but the point-of-care sector was always significant, even before the pandemic. Point-of-care markets (and the companies that served them) grew faster than other markets.

January 3, 2022

Natera touts data supporting personalized ctDNA testing

The data were presented at the virtual European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer, which was held from July 1 to 4, and support the validity of Natera's Signatera ctDNA test for identifying molecular residual disease in patients with this type of cancer. The test is customized for each individual, based on the clonal mutations in his or her tumor, according to the company.

July 6, 2020

More stool PCR testing likely needed in COVID-19 patients

COVID-19 is commonly seen as a respiratory disease and much of the focus for diagnosis and also discharge of patients from hospitals following recovery has understandably been on the status of respiratory specimens. But gastrointestinal symptoms are also part of the disease and deserve more attention to help "prevent further spread of this highly contagious pathogen," wrote Dr. Sravanthi Parasa, a gastroenterologist at Swedish Medical Center in Seattle, and colleagues.

June 11, 2020

Jury is still out on SARS-CoV-2 intermediate host

One researcher from the University of Ottawa provides genomic evidence that dogs may be an intermediate carrier, while another study from Chinese researchers suggests that canines would be a poor transmitter of the virus.

April 16, 2020

Meridian acquires GenePOC from Debiopharm

Through the deal, Meridian will gain GenePOC's revogene product for microbial testing, which incorporates polymerase chain reaction (PCR) techniques for rapid testing in cases where infectious diseases are suspected. The product is marketed in the U.S., Europe, and Canada.

April 30, 2019

Page 1 of 1